Refametinib

CAS No.

923032-37-5

MDL No.

MFCD18633256

C₁₉H₂₀F₃IN₂O₅S

572.30

InChI Key

RDSACQWTXKSHJT-NSHDSACASA-N

Pack Size	Purity	Price	Availability
1 mg	99%	$30	In Stock
5 mg	99%	$34	In Stock
10 mg	99%	$54	In Stock
50 mg	99%	$178	In Stock
100 mg	99%	$329	In Stock
Custom synthesis and bulk supply options are available upon request.

Pack Size

Purity

Price

Availability

Action

1 mg

99%

$30

In Stock

5 mg

99%

$34

In Stock

10 mg

99%

$54

In Stock

50 mg

99%

$178

In Stock

100 mg

99%

$329

In Stock

Custom synthesis and bulk supply options are available upon request.

Product Information

Refametinib is an orally bioavailable, selective MEK inhibitor with potential antineoplastic activity. It specifically inhibits MAP2K1 (MAPK/ERK kinase 1), thereby blocking growth factor-mediated cell signaling and tumor cell proliferation.

CAS No.	923032-37-5
Product Name	Refametinib

Biological Targets

MAP2K1·MAP2K2

Associated Conditions

hepatocellular carcinoma·biliary tract cancer·cancer·neoplasm

* The information provided here is compiled from public sources and is for reference only.

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Documentation

Refametinib

Pricing & Availability

Product Information

Biological Profile

Safety Information

Properties

Biological Targets

Associated Conditions

Related Articles

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.

Observations on the mechanism of antitumour resistance induced by the graft-versus-host reaction.

Documentation